ANAPC1P1: A Drug Target / Disease Biomarker (G100286979)

Target Name: ANAPC1P1

NCBI ID: G100286979

ANAPC1P1

Other Name(s): ANAPC1 pseudogene 1

ANAPC1P1: A Drug Target / Disease Biomarker

ANAPC1P1, also known as ANAPC1, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. The ANAPC1P1 gene is located on chromosome 12 and encodes a protein known as ANAPC1P1, which is a key regulator of the cell cycle and has been shown to play a role in the development and progression of various diseases.

One of the key features of ANAPC1P1 is its ability to interact with and regulate the activity of other genes. This interaction with other genes is crucial for the proper functioning of the cell and is often disrupted in diseases such as cancer. By studying the ANAPC1P1 gene and its associated proteins, researchers have identified several potential drug targets or biomarkers that could be used to treat a range of diseases.

One of the most promising aspects of ANAPC1P1 is its potential as a cancer drug target. Cancer is a leading cause of death worldwide, and there is a high demand for new and effective treatments. ANAPC1P1 has been shown to play a role in the development and progression of various types of cancer, including breast, ovarian, and prostate cancers.

In addition to its potential as a cancer drug target, ANAPC1P1 has also been identified as a potential biomarker for cancer. The ANAPC1P1 gene has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancers. This suggests that ANAPC1P1 could be used as a biomarker for cancer, potentially allowing for earlier detection and more effective treatment.

ANAPC1P1 has also been shown to play a role in the regulation of the cell cycle. The cell cycle is the process by which cells grow, divide, and replicate themselves, and it is a crucial aspect of cell growth and development. ANAPC1P1 has been shown to regulate the length of the cell cycle and to disrupt the normal progression of the cell cycle in cancer cells.

This disruption of the cell cycle is thought to contribute to the development and progression of cancer. By targeting the ANAPC1P1 gene and its associated proteins, researchers have identified several potential drug targets or biomarkers that could be used to treat a range of diseases, including cancer.

In conclusion, ANAPC1P1 is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its ability to interact with and regulate the activity of other genes and its potential as a cancer drug target and biomarker make it an attractive target for research and development of new treatments. Further studies are needed to fully understand the role of ANAPC1P1 in disease and to develop effective treatments.

Protein Name: ANAPC1 Pseudogene 1

The "ANAPC1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANAPC1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets